Mode
Text Size
Log in / Sign up
Phase 2 Completed N=218 Randomized Triple-blind Treatment

Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency

Alcoholism · Alcohol Abuse
Source: ClinicalTrials.gov NCT00498628 ↗
Enrolled (actual)
218
Serious AEs
5.1%
Results posted
May 2012
Primary outcomePrimary: Percent Heavy Drinking Days — 37.1; 37.9 percentage of heavy drinking days

Summary

The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Heavy Drinking Days
37.1; 37.9
SECONDARY
Percent Days Abstinent
49.5; 47.1
SECONDARY
Drinks Per Drinking Day
6.2; 6.3
SECONDARY
Drinks Per Day
4.3; 4.4
SECONDARY
Percent Very Heavy Drinking Day
16.5; 18.8
SECONDARY
Percent Subjects Abstinent
12; 12
SECONDARY
Percent Subjects With no Heavy Drinking Day
17; 24
SECONDARY
Drinking Consequences Score
18.5; 22.5
SECONDARY
Penn Alcohol Craving Score (PACS_
12.1; 12.8
SECONDARY
Montgomery-Asberg Depression Rating Scale (MADRS)
2.8; 4.1
SECONDARY
Hamilton Anxiety Scale (HAM-A)
2.4; 3.0
SECONDARY
Pittsburgh Sleep Quality Score
4.1; 5.1
SECONDARY
Quality of Life SF - 12 - Mental Aggregate Score
51.5; 50.7
SECONDARY
Quality of Life SF-12 - Physical Aggregate Score
51.0; 50.6

Eligibility Criteria

Inclusion Criteria

  • Between the ages of 18 and 65 years old
  • DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E
  • Report "very heavy" drinking (10 or more drinks per drinking day for men or 8 or more drinks per drinking day for women) at least 40% of the days during the interval from day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this 60-day period), with at least one day of "very heavy" drinking occurring within the last 2 weeks before screening
  • Seeking treatment for alcohol dependence and desire reduction or cessation of drinking
  • Able to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures
  • Females of child bearing potential must agree to use of at least one approved method of birth control, or must be surgically sterile or postmenopausal
  • Able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits
  • Able to understand written and oral instructions in English and to complete the questionnaires required by the protocol
  • Can complete all psychological assessments required at screening and baseline
  • Able to provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to study site, and have no plans to move within the next 3 months or unresolved legal problems; must provide contact information of family member, spouse, or significant other who can contact subject in case of missed appointment
  • Breath alcohol concentration (BAC) equal to 0.00 when s/he signed the informed consent document
  • Must have an absolute neutrophil count of 1.5 x 109/L or greater.

Exclusion Criteria

Please contact site for additional information.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00498628). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search